Gritstone bio, Inc. Common Stock
GRTS
GRTS was delisted on the 21st of October, 2024.
63 hedge funds and large institutions have $321M invested in Gritstone bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 7 reducing their positions, and 9 closing their positions.
343% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 7
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $244M → $321M (+$77M)
17.54% more ownership
Funds ownership: 63.24% → 80.78% (+18%)
17% more funds holding
Funds holding: 54 → 63 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$35.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.9M |
| 3 |
BlackRock
New York
|
+$12.7M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$9.86M |
| 5 |
CC
Casdin Capital
New York
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.98M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$213K |
| 3 |
Squarepoint
New York
|
-$159K |
| 4 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$141K |
| 5 |
PIM
Partner Investment Management
San Francisco,
California
|
-$116K |
GRTS Hedge Fund Activity: Q2 2019 in Review
63 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Gritstone bio, Inc. Common Stock (GRTS) for Q2 2019, worth a combined $321M — up 32% from $244M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new GRTS positions and 9 closed out — a net gain of 10 holders — while 31 added to existing stakes and 7 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $35.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $4.98M sold.
- 63 institutional investors held Gritstone bio, Inc. Common Stock (GRTS) as of Q2 2019, up from 54 in Q1 2019.
- Funds reported $321M of Gritstone bio, Inc. Common Stock stock for Q2 2019, up 32% quarter-over-quarter.
- 19 funds opened new Gritstone bio, Inc. Common Stock positions in Q2 2019 and 9 closed out, a net change of +10 holders.
- The largest Gritstone bio, Inc. Common Stock buyer in Q2 2019 was Versant Venture Management, an estimated $35.5M added.
- The largest Gritstone bio, Inc. Common Stock seller in Q2 2019 was PFM Health Sciences, an estimated $4.98M sold.
Based on aggregated 13F filings for Q2 2019.